DE69534727D1 - Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen - Google Patents

Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen

Info

Publication number
DE69534727D1
DE69534727D1 DE69534727T DE69534727T DE69534727D1 DE 69534727 D1 DE69534727 D1 DE 69534727D1 DE 69534727 T DE69534727 T DE 69534727T DE 69534727 T DE69534727 T DE 69534727T DE 69534727 D1 DE69534727 D1 DE 69534727D1
Authority
DE
Germany
Prior art keywords
synthesis
boric acid
ester compounds
disclosed
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534727T
Other languages
English (en)
Other versions
DE69534727T2 (de
Inventor
Julian Adams
Yu-Ting Ma
Ross Stein
Matthew Baevsky
Louis Grenier
Louis Plamondon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69534727(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of DE69534727D1 publication Critical patent/DE69534727D1/de
Application granted granted Critical
Publication of DE69534727T2 publication Critical patent/DE69534727T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69534727T 1994-10-28 1995-10-27 Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen Expired - Lifetime DE69534727T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33052594A 1994-10-28 1994-10-28
US330525 1994-10-28
US08/442,581 US6083903A (en) 1994-10-28 1995-05-16 Boronic ester and acid compounds, synthesis and uses
US442581 1995-05-16

Publications (2)

Publication Number Publication Date
DE69534727D1 true DE69534727D1 (de) 2006-02-02
DE69534727T2 DE69534727T2 (de) 2006-09-14

Family

ID=26987313

Family Applications (5)

Application Number Title Priority Date Filing Date
DE200412000025 Pending DE122004000025I1 (de) 1994-10-28 1995-10-27 Borons{ure-und-Esterverbindungen, deren Systhese und Verwendungen.
DE69534727T Expired - Lifetime DE69534727T2 (de) 1994-10-28 1995-10-27 Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen
DE1995630936 Active DE122004000025I2 (de) 1994-10-28 1995-10-27 Borons{ure-und-esterverbindungen, deren Systhese und Verwendungen
DE69530936T Expired - Lifetime DE69530936T3 (de) 1994-10-28 1995-10-27 Boronsäure-und-esterverbindungen, deren systhese und verwendungen
DE69535866T Expired - Lifetime DE69535866D1 (de) 1994-10-28 1995-10-27 Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE200412000025 Pending DE122004000025I1 (de) 1994-10-28 1995-10-27 Borons{ure-und-Esterverbindungen, deren Systhese und Verwendungen.

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE1995630936 Active DE122004000025I2 (de) 1994-10-28 1995-10-27 Borons{ure-und-esterverbindungen, deren Systhese und Verwendungen
DE69530936T Expired - Lifetime DE69530936T3 (de) 1994-10-28 1995-10-27 Boronsäure-und-esterverbindungen, deren systhese und verwendungen
DE69535866T Expired - Lifetime DE69535866D1 (de) 1994-10-28 1995-10-27 Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen

Country Status (25)

Country Link
US (16) US6083903A (de)
EP (4) EP1312609B1 (de)
JP (1) JP3717934B2 (de)
KR (1) KR100398944B1 (de)
CN (2) CN1305475C (de)
AT (3) ATE314378T1 (de)
AU (1) AU710564B2 (de)
CA (2) CA2496538C (de)
CH (1) CH0788360H1 (de)
CY (1) CY2484B1 (de)
DE (5) DE122004000025I1 (de)
DK (3) DK1627880T3 (de)
ES (3) ES2254803T3 (de)
FI (2) FI114801B (de)
FR (1) FR04C0014I2 (de)
HK (2) HK1002059A1 (de)
IL (5) IL133831A (de)
LU (1) LU91083I2 (de)
MX (1) MX9703063A (de)
NL (1) NL300151I2 (de)
NO (2) NO310558B1 (de)
NZ (2) NZ337211A (de)
PT (3) PT1312609E (de)
TW (1) TW318850B (de)
WO (1) WO1996013266A1 (de)

Families Citing this family (302)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
FR2758329B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
US6271199B2 (en) * 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP1017398A1 (de) * 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitoren, inhibitoren des ubiquitinweges oder verbindungen, die mit der durch den ubiquitinweg enstehenden nf-kb aktivierung interferieren zur behandlung von entzündlichen und autoimmunerkrankungen
CA2304206A1 (en) * 1997-09-29 1999-04-08 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
DE19802450A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP0982317A1 (de) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalente Proteasome Inhibitore
US6613541B1 (en) * 1998-10-20 2003-09-02 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
WO2002014381A2 (en) * 2000-08-16 2002-02-21 University Of Alberta Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
US6919382B2 (en) 2000-08-31 2005-07-19 The Governors Of The University Of Alberta Preparation and uses of conjugated solid supports for boronic acids
EP2301565A1 (de) * 2000-10-12 2011-03-30 ViroLogik GmbH Verwendung von Proteasome Hemmern zur Behandlung von Virus-Infektionen
ATE501157T1 (de) * 2001-01-25 2011-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulierungen von borsäure-verbindungen
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6740674B2 (en) 2001-05-21 2004-05-25 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
DE60209227T2 (de) * 2001-05-30 2006-08-17 Novartis Ag 2-((n-(2-amino-3-(heteroaryl- oder -aryl)propionyl)aminoacyl)amino)-alkylboronsäurederivate
WO2003033506A1 (fr) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
WO2003033507A1 (fr) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
WO2003059898A2 (en) * 2002-01-08 2003-07-24 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
EP1487459A4 (de) * 2002-03-12 2006-05-24 Ariad Pharma Inc Peptid-analoga und ihre verwendung
DK1485354T3 (da) 2002-03-13 2008-09-01 Janssen Pharmaceutica Nv Sulfonylamino-derivater som nye inhibitorer af histandeacetylase
US7592450B2 (en) * 2002-03-13 2009-09-22 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as inhibitors of histone deacetylase
DK1485348T3 (da) * 2002-03-13 2008-09-29 Janssen Pharmaceutica Nv Carbonylamino-derivater som nye inhibitorer af histandeacetylase
JP4472353B2 (ja) 2002-03-13 2010-06-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのアミノ誘導体
DE50313092D1 (de) * 2002-04-05 2010-10-28 Virologik Gmbh Mittel zur behandlung von flaviviridae-infektionen
WO2003106384A2 (en) * 2002-06-01 2003-12-24 Johns Hopkins University Novel boronic chalcone derivatives and uses thereof
EP1578434A2 (de) * 2002-07-09 2005-09-28 Point Therapeutics, Inc. Verfahren und zusammensetzung in bezug auf isoleucin-boroprolin-verbindungen
AU2003271747B2 (en) * 2002-08-14 2008-09-11 Janssen Pharmaceutica N.V. Use of NF-kappa B inhibitors for the treatment of mastitis
JP2006511593A (ja) * 2002-09-09 2006-04-06 トライジェン・リミテッド ボロン酸塩および血栓症の治療におけるその使用
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US20050119226A1 (en) * 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
US7112572B2 (en) * 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
US20050282757A1 (en) * 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
US20050176651A1 (en) * 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
EP1542768A1 (de) * 2002-09-20 2005-06-22 Alcon, Inc. Verwendung von zytokin-synthesehemmern zur behandlung von erkrankungen mit trockenem auge
EP1581629B1 (de) 2002-12-06 2015-04-01 Millennium Pharmaceuticals, Inc. Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einer proteasomen inhibitions therapie
CN100341880C (zh) * 2003-02-13 2007-10-10 上海仁虎制药股份有限公司 新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
WO2005007211A2 (en) * 2003-07-03 2005-01-27 Medtronic Vascular Inc. Medical devices with proteasome inhibitors for the treatment of restenosis
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
MXPA06005104A (es) 2003-11-05 2007-01-25 Palingen Inc Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim.
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
CA2558106A1 (en) * 2004-02-23 2005-09-09 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
RS51983B (en) * 2004-03-30 2012-02-29 Millennium Pharmaceuticals Inc. SYNTHESIS OF ORGANOBORIC ACID AND ORGANOBORIC ACID COMPOUNDS
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
CN102174076A (zh) 2004-04-15 2011-09-07 普罗特奥里克斯公司 用于抑制蛋白酶体酶的化合物
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CA2565407A1 (en) 2004-05-10 2005-11-24 Proteolix, Inc. Compounds for enzyme inhibition
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
NZ552865A (en) 2004-07-28 2009-09-25 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
EP2100899A3 (de) 2004-10-20 2009-09-30 Proteolix, Inc. Verbindungen zur Enzyminhibition
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
WO2006052641A2 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
KR101346886B1 (ko) 2005-01-21 2014-01-02 아스텍스 테라퓨틱스 리미티드 제약 화합물
CA2595749A1 (en) * 2005-01-27 2006-08-03 Research Development Foundation Combination therapy with triterpenoid compounds and proteasome inhibitors
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
HUE040060T2 (hu) 2005-02-16 2019-02-28 Anacor Pharmaceuticals Inc Halogén-szubsztituált boronftalidok fertõzések kezelésére
WO2006099261A2 (en) * 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
KR20080007642A (ko) * 2005-04-29 2008-01-22 코산 바이오사이언시즈, 인코포레이티드 프로테아좀 억제제와 함께 17-ａａｇ 또는 17-ａｇ 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
AU2006248938B2 (en) 2005-05-18 2011-09-29 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
ES2400916T3 (es) * 2005-06-08 2013-04-15 Janssen Biotech, Inc. Una terapia celular para degeneración ocular
US20090017006A1 (en) * 2005-07-06 2009-01-15 Biodevelops Pharma Entwicklung Gmbh Use of a compound for enhancing the expression of membrane proteins on the cell surface
US7531517B2 (en) 2005-08-10 2009-05-12 4Sc Ag Inhibitors of cancer cell, T-cell and keratinocyte proliferation
EP1752467A1 (de) 2005-08-10 2007-02-14 4Sc Ag Krebszellen-, t-Zellen- und Keratinocyte-Proliferation-Inhibitoren
US20070059382A1 (en) * 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
NZ568068A (en) 2005-11-09 2011-10-28 Proteolix Inc Compounds for enzyme inhibition
US20090221488A1 (en) * 2005-12-08 2009-09-03 Wood Kenneth W Certain Compositions and Methods of Treatment
CN106008583A (zh) 2005-12-30 2016-10-12 安纳考尔医药公司 含硼的小分子
ES2396986T3 (es) * 2006-01-19 2013-03-01 Janssen Pharmaceutica N.V. Derivados de piridina y pirimidina como inhibidores de histona desacetilasa
PL1981874T3 (pl) * 2006-01-19 2009-10-30 Janssen Pharmaceutica Nv Pochodne aminofenylowe jako nowe inhibitory deacetylazy histonowej
CA2631874C (en) * 2006-01-19 2014-11-18 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DK1981875T3 (da) * 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US8168614B2 (en) 2006-02-16 2012-05-01 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
US20090312284A1 (en) * 2006-09-15 2009-12-17 Janine Arts Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
AU2007296259A1 (en) * 2006-09-15 2008-03-20 Janssen Pharmaceutica Nv Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CA2606634A1 (en) * 2006-12-08 2008-06-08 Centenary Institute Of Cancer Medicine And Cell Biology Assay for response to proteasome inhibitors
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CA2695225C (en) 2007-07-31 2021-06-01 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
TW200911237A (en) 2007-08-03 2009-03-16 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
DK2178888T3 (da) 2007-08-06 2012-10-01 Millennium Pharm Inc Proteasomhæmmere
US7442830B1 (en) * 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009036281A2 (en) * 2007-09-12 2009-03-19 Dr. Reddy's Laboratories Ltd. Bortezomib and process for producing same
US20090076031A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bortezomib
ES2578905T5 (es) 2007-10-04 2020-03-18 Onyx Therapeutics Inc Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
US9062290B2 (en) * 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
CN101220048B (zh) * 2007-12-14 2012-08-15 江苏先声药物研究有限公司 ZnCl2催化下的蒎烷二醇酯的制备方法
ES2437595T3 (es) 2007-12-20 2014-01-13 Novartis Ag Derivados de tiazol usados como inhibidores de la PI 3 quinasa
BR122017025207B1 (pt) 2008-02-21 2021-03-16 Centocor Ortho Biotech Inc superfície que faz parte de um recipiente ou matriz destinada para uso em uma cultura de células ou análises, desprovida de uma camada de células alimentadoras e desprovida de uma camada adsorvente
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
EP2285384A4 (de) * 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc Borhaltige kleine moleküle
UA115131C2 (uk) * 2008-06-17 2017-09-25 Мілленніум Фармасьютікалз, Інк. Сполуки боронатного ефіру і його фармацевтичні рецептури
ES2697798T3 (es) 2008-06-30 2019-01-28 Janssen Biotech Inc Diferenciación de células madre pluripotentes
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (de) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Borhaltige kleine moleküle
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010048298A1 (en) * 2008-10-21 2010-04-29 Proteolix, Inc. Combination therapy with peptide epoxyketones
CN107904201B (zh) 2008-10-31 2021-11-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
CN107435038B (zh) 2008-10-31 2021-07-09 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
KR101837080B1 (ko) 2008-11-20 2018-03-09 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
BRPI0921996A2 (pt) * 2008-11-20 2015-08-18 Centocor Ortho Biotech Inc Métodos e composições para cultura e ligação de células em substratos planos.
CN101747354B (zh) * 2008-12-04 2014-08-13 江苏先声药物研究有限公司 一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
US8461364B2 (en) * 2008-12-17 2013-06-11 Glaxosmithkline Llc Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C][1,2]oxaborol-1-OL
EP2379077A4 (de) * 2009-01-09 2013-09-11 Sun Pharma Advanced Res Co Ltd Pharmazeutische zusammensetzung
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
WO2010105008A2 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
US9605317B2 (en) 2009-03-24 2017-03-28 Janssen Pharmaceutica Nv Biomarkers for assessing peripheral neuropathy response to cancer treatment
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
JP2012522055A (ja) * 2009-03-30 2012-09-20 セルリアン・ファーマ・インコーポレイテッド ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
AU2009347159B2 (en) * 2009-05-27 2015-09-03 Cephalon, Inc. Combination therapy for the treatment of multiple myeloma
EP2443128B1 (de) 2009-06-19 2017-12-20 LEK Pharmaceuticals d.d. Neue synthetische Route zur Herstellung von alpha-Aminoboronsäure-estern
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
EP2280016A1 (de) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. Neue synthetische Route zur Herstellung von Alpha-Aminoborestern über substituierte Alylene
EP2270019A1 (de) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. Neue synthetische Route zur Herstellung von alpha-Aminoborestern
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
DE102009027754A1 (de) 2009-07-15 2011-05-05 Schubert, Ulrich, Dr. Verfahren zur Hemmung der Reifung von dendritischen Zellen
JP5819826B2 (ja) 2009-07-20 2015-11-24 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
EP2456862A4 (de) 2009-07-20 2013-02-27 Janssen Biotech Inc Differenzierung menschlicher embryonischer stammzellen
WO2011011302A2 (en) * 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
WO2011017125A1 (en) * 2009-07-28 2011-02-10 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
WO2011019618A1 (en) * 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011022502A1 (en) 2009-08-18 2011-02-24 Georgetown University Boronic acid compositions and methods related to cancer
WO2011022337A1 (en) * 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011029802A1 (en) 2009-09-08 2011-03-17 F. Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
EP2305285A1 (de) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
PL2519231T3 (pl) 2009-10-01 2017-09-29 Janssen Pharmaceutica Nv Inhibitory proteasomów do leczenia raka
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110212918A1 (en) * 2009-11-11 2011-09-01 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
KR101867369B1 (ko) 2009-12-23 2018-06-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
KR101923537B1 (ko) 2009-12-23 2018-11-29 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
BR112012022060A2 (pt) * 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
JP6013196B2 (ja) * 2010-03-01 2016-10-25 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞から誘導した細胞を精製するための方法
NZ602392A (en) * 2010-03-18 2014-03-28 Innopharma Inc Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
NZ602622A (en) * 2010-03-31 2015-01-30 Millennium Pharm Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
AU2013204868B2 (en) * 2010-03-31 2016-10-13 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
RU2012147246A (ru) 2010-04-07 2014-05-20 Оникс Терапьютикс, Инк. Кристаллический пептидный эпоксикетонный ингебитор иммунопротеасомы
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
CN102946879B (zh) 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
DK2569419T3 (da) 2010-05-12 2019-05-13 Janssen Biotech Inc Differentiering af humane embryoniske stamceller
EP2571525A4 (de) 2010-05-18 2016-04-27 Cerulean Pharma Inc Zusammensetzungen und verfahren zur behandlung von autoimmun- und anderen erkrankungen
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
SG187947A1 (en) 2010-08-31 2013-03-28 Janssen Biotech Inc Differentiation of pluripotent stem cells
SG187946A1 (en) 2010-08-31 2013-03-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
SG10201506852VA (en) 2010-08-31 2015-10-29 Janssen Biotech Inc Differentiation of human embryonic stem cells
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
ES2635333T3 (es) 2010-09-07 2017-10-03 Anacor Pharmaceuticals, Inc. Derivados de benzoxaborol para tratar infecciones bacterianas
AU2011312264B2 (en) 2010-10-05 2015-07-02 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
EP2627636B1 (de) 2010-10-14 2015-09-02 Synthon BV Verfahren zur herstellung von bortezomib und den zwischenprodukten für das verfahren
CN103476777B (zh) 2011-01-31 2015-05-27 诺瓦提斯公司 新杂环衍生物
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
WO2012135528A2 (en) 2011-03-29 2012-10-04 Texas Tech University System Galectin-3c combination therapy for human cancer
BR112013025005A2 (pt) 2011-03-31 2017-01-17 Nanocarrier Co Ltd composição farmacêutica contendo copolímero por blocos compreendendo composto de ácido borônico
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2012177835A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
US8481655B2 (en) 2011-07-27 2013-07-09 Wacker Chemical Corporation Copper complexes of amino-functional organosilicon compounds and their use
WO2013021032A1 (en) 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
RS55053B1 (sr) 2011-08-11 2016-12-30 Janssen Pharmaceutica Nv Prediktori za lečenje kancera
EA032841B1 (ru) 2011-08-19 2019-07-31 Глаксо Груп Лимитед Соединения для получения бензофуранового соединения для лечения инфекций, вызываемых вирусом гепатита с
EP2753334B1 (de) 2011-08-30 2022-10-19 Trustees Of Tufts College Fap-aktivierte proteasomhemmer zur behandlung fester tumore
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
CN104080926B (zh) 2011-10-28 2019-04-23 米伦纽姆医药公司 对nedd8活化酶(nae)抑制剂的反应的生物标记
JP6397765B2 (ja) 2011-11-11 2018-09-26 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
CA2855368A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
IN2014CN03580A (de) 2011-11-17 2015-10-09 Univ Tokyo
KR102090751B1 (ko) 2011-12-22 2020-03-19 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
JP6215235B2 (ja) 2012-01-24 2017-10-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療方法
WO2013112881A1 (en) 2012-01-27 2013-08-01 Thomas Jefferson University Mct protein inhibitor-related prognostic and therapeutic methods
US9409976B2 (en) 2012-02-08 2016-08-09 Igm Biosciences, Inc. CDIM binding proteins and uses thereof
EP2819673B1 (de) 2012-03-02 2016-09-07 Dr. Reddy's Laboratories Ltd. Pharmazeutische zusammensetzungen mit borsäureverbindungen
SG11201405052RA (en) 2012-03-07 2014-10-30 Janssen Biotech Inc Defined media for expansion and maintenance of pluripotent stem cells
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
AU2013263043B2 (en) 2012-05-16 2016-06-16 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
CA2875786C (en) 2012-06-08 2022-12-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
TW201414751A (zh) 2012-07-09 2014-04-16 歐尼克斯治療公司 肽環氧酮蛋白酶抑制劑之前驅藥物
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
CN104822688A (zh) * 2012-09-11 2015-08-05 西普拉有限公司 制备硼替佐米的方法
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
JP2015536342A (ja) 2012-11-16 2015-12-21 シルパ・メディケア・リミテッドＳｈｉｌｐａ Ｍｅｄｉｃａｒｅ Ｌｉｍｉｔｅｄ 結晶ボルテゾミブの方法
WO2014097306A1 (en) 2012-12-21 2014-06-26 Natco Pharma Limited Stable and pure polymorphic form of bortezomib
WO2014105546A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
BR112015015770A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
WO2014106141A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
WO2014170628A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester
EP2986290A4 (de) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1-verwandte verfahren zur behandlung von glioblastom mit temozolomid
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
KR20160058886A (ko) 2013-10-03 2016-05-25 밀레니엄 파머슈티컬스 인코퍼레이티드 전신 홍반성 낭창 및/또는 낭창성 신염의 예방 또는 치료 방법
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
JP6468562B2 (ja) * 2013-11-21 2019-02-13 国立大学法人北海道大学 プロテアソーム阻害性化合物
WO2015085097A1 (en) * 2013-12-05 2015-06-11 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
WO2015083101A1 (en) 2013-12-06 2015-06-11 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EP3102585B1 (de) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Boronsäureester und pharmazeutische formulierungen daraus
EP2910557A1 (de) * 2014-02-20 2015-08-26 Ikerchem, S.L. Enantiomerenreine tetrasubstituierte Pyrrolidine als Gerüste für Proteasomhemmer und medizinische Anwendungen davon
WO2015170757A1 (ja) 2014-05-08 2015-11-12 国立大学法人 東京大学 医薬組成物
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
EA201692332A1 (ru) 2014-05-20 2017-04-28 Милленниум Фармасьютикалз, Инк. Борсодержащие ингибиторы протеасом для применения после первичной противораковой терапии
EP4180041A1 (de) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Verbindungen und verfahren zur behandlung von krebs
RU2017115191A (ru) * 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
WO2016110870A1 (en) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Pharmaceutical composition of bortezomid
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
US20180243217A1 (en) 2015-03-17 2018-08-30 Leon-Nanodrugs Gmbh Nanoparticles comprising a stabilized boronic acid compound
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
WO2016205790A2 (en) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3120837A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
CN106478700B (zh) * 2015-08-26 2020-12-29 杭州雷索药业有限公司 硼基取代的苯胺类蛋白激酶抑制剂
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
EP3370719A1 (de) 2015-11-02 2018-09-12 Novartis AG Dosierungsplan für einen phosphatidylinositol-3-kinase-inhibitor
US11111296B2 (en) 2015-12-14 2021-09-07 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN107151254A (zh) * 2016-03-06 2017-09-12 复旦大学 一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
CA3025253A1 (en) 2016-06-21 2017-12-28 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
JP6681284B2 (ja) * 2016-06-23 2020-04-15 信越化学工業株式会社 糖アルコール化合物の金属低減方法
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
JP2020500839A (ja) 2016-10-20 2020-01-16 ファイザー・インク ペプチドボロン酸またはボロン酸エステル化合物を有する治療用粒子ならびにその作製および使用方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN110312727A (zh) 2017-02-17 2019-10-08 费森尤斯卡比肿瘤学有限公司 一种改进的制备硼酸酯的方法
CA3054572A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN111601597B (zh) 2017-08-23 2023-10-13 科智生命科学公司 自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
CA3075714A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
HUE060020T2 (hu) * 2017-11-16 2023-01-28 Principia Biopharma Inc Immunproteaszóma-gátlók
EP3710458A1 (de) 2017-11-16 2020-09-23 Principia Biopharma Inc. Immunproteasominhibitoren
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CA3087565A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TW202003553A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
EP3873214A4 (de) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Feste formen von (4-(2-fluor-4-(1-methyl-1h-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanon
CN109824756B (zh) * 2019-03-19 2022-03-22 山东大学 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
CN114437119A (zh) * 2020-10-30 2022-05-06 苏州开拓药业股份有限公司 一种c-Myc蛋白抑制剂及其制备方法和用途
WO2022120039A2 (en) * 2020-12-02 2022-06-09 Steven Hoffman Compositions and methods for modulating cancer in non-human mammals
TW202237143A (zh) * 2020-12-10 2022-10-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
EP4134083A1 (de) 2021-08-12 2023-02-15 Extrovis AG Pharmazeutische zusammensetzungen von bortezomib
CN113957441B (zh) * 2021-10-29 2024-01-02 光华科学技术研究院(广东)有限公司 蚀刻液及其制备方法和应用
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261868A (en) * 1979-08-08 1981-04-14 Lever Brothers Company Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound
US4369183A (en) * 1979-09-06 1983-01-18 Merck & Co., Inc. 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4537707A (en) * 1984-05-14 1985-08-27 The Procter & Gamble Company Liquid detergents containing boric acid and formate to stabilize enzymes
US4842769A (en) * 1985-07-26 1989-06-27 Colgate-Palmolive Co. Stabilized fabric softening built detergent composition containing enzymes
US4759032A (en) 1987-06-03 1988-07-19 Monsanto Company Electrode seal assembly
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
KR960012512B1 (ko) 1987-06-19 1996-09-20 캔디스 엘. 볼커 신규한 종류의 저칼로리 단백질 감미제
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US4963655A (en) * 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US4959179A (en) * 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5030378A (en) * 1990-01-02 1991-07-09 The Procter & Gamble Company Liquid detergents containing anionic surfactant, builder and proteolytic enzyme
CA2077665A1 (en) 1990-03-05 1991-09-06 Robert Siman Chymotrypsin-like proteases and their inhibitors
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
EP0478050A1 (de) * 1990-09-24 1992-04-01 Unilever N.V. Detergentzusammensetzung
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
EP0564552A1 (de) * 1990-12-28 1993-10-13 Cortex Pharmaceuticals, Inc. Verwendung von calpaininhibitoren zur hemmung und behandlung von neurodegeneration
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
EP0564561A4 (en) * 1990-12-28 1994-08-10 Georgia Tech Res Inst Peptides ketoamides, ketoacids, and ketoesters
EP0511456A1 (de) * 1991-04-30 1992-11-04 The Procter & Gamble Company Flüssiges Reinigungsmittel mit einem aromatischen Boratester zur Inhibierung des proteolytischen Enzyms
AU666660B2 (en) * 1991-04-30 1996-02-22 Procter & Gamble Company, The Built liquid detergents with boric-polyol complex to inhibit proteolytic enzyme
AU2014892A (en) * 1991-04-30 1992-12-21 Procter & Gamble Company, The Liquid detergents with an aryl boronic acid
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
AU4077193A (en) * 1992-04-16 1993-11-18 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
JPH07505877A (ja) * 1992-04-16 1995-06-29 ゼネカ・リミテッド α−アミノボロン酸ペプチド及びエラスターゼ阻害剤としてのそれらの使用
ES2098484T3 (es) 1992-08-14 1997-05-01 Procter & Gamble Detergentes liquidos que contienen un acido alfa-amino-boronico.
WO1994017816A1 (en) 1993-02-10 1994-08-18 The President And Fellows Of Harvard College Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5424904A (en) * 1993-10-04 1995-06-13 Taylor, Sr.; Thomas T. Circuit for electrically controlled intermittent motion
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) * 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
ATE501157T1 (de) 2001-01-25 2011-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulierungen von borsäure-verbindungen
RS51983B (en) 2004-03-30 2012-02-29 Millennium Pharmaceuticals Inc. SYNTHESIS OF ORGANOBORIC ACID AND ORGANOBORIC ACID COMPOUNDS

Also Published As

Publication number Publication date
CN1305475C (zh) 2007-03-21
DE69535866D1 (de) 2008-11-27
EP0788360B1 (de) 2003-05-28
LU91083I9 (de) 2018-12-28
ES2254803T3 (es) 2006-06-16
JP3717934B2 (ja) 2005-11-16
US20020173488A1 (en) 2002-11-21
DK0788360T3 (da) 2003-09-22
CN101077875A (zh) 2007-11-28
CN101077875B (zh) 2011-01-26
WO1996013266A1 (en) 1996-05-09
PT1627880E (pt) 2009-01-23
EP1627880A1 (de) 2006-02-22
FR04C0014I2 (de) 2005-05-21
IL115790A0 (en) 1996-01-19
ES2199257T3 (es) 2004-02-16
US20110306560A1 (en) 2011-12-15
CA2203936C (en) 2005-04-12
DE122004000025I1 (de) 2004-09-30
DE69530936C5 (de) 2007-02-22
AU710564C (en) 1996-05-23
US20130310320A1 (en) 2013-11-21
IL137726A (en) 2004-08-31
KR100398944B1 (ko) 2004-06-04
KR970706824A (ko) 1997-12-01
ATE314378T1 (de) 2006-01-15
FI120974B (fi) 2010-05-31
HK1002059A1 (en) 1998-07-31
IL133831A0 (en) 2001-04-30
DE69530936T2 (de) 2004-02-26
EP0788360A1 (de) 1997-08-13
ES2314540T3 (es) 2009-03-16
DE69530936D1 (de) 2003-07-03
US20040167332A1 (en) 2004-08-26
IL115790A (en) 2002-12-01
CH0788360H1 (de) 2006-03-15
DE69530936T3 (de) 2010-08-26
US8003791B2 (en) 2011-08-23
US6297217B1 (en) 2001-10-02
NL300151I1 (nl) 2004-08-02
CA2496538A1 (en) 1996-05-09
NL300151I2 (nl) 2004-09-01
NO310558B1 (no) 2001-07-23
CA2203936A1 (en) 1996-05-09
PT1312609E (pt) 2006-05-31
HK1087714A1 (en) 2006-10-20
EP1627880B1 (de) 2008-10-15
TW318850B (de) 1997-11-01
US20080132678A1 (en) 2008-06-05
CY2484B1 (en) 2005-06-03
US7119080B2 (en) 2006-10-10
FI114801B (fi) 2004-12-31
FI971746A0 (fi) 1997-04-23
AU710564B2 (en) 1999-09-23
IL133831A (en) 2004-03-28
US20150072942A1 (en) 2015-03-12
JPH10510245A (ja) 1998-10-06
AU4139896A (en) 1996-05-23
US20030199561A1 (en) 2003-10-23
US6465433B1 (en) 2002-10-15
NZ296717A (en) 1999-11-29
DK0788360T5 (da) 2017-09-18
EP1997823A1 (de) 2008-12-03
EP1312609B1 (de) 2005-12-28
EP0788360B3 (de) 2009-08-12
US6083903A (en) 2000-07-04
NO971929L (no) 1997-06-12
US20070282100A1 (en) 2007-12-06
FR04C0014I1 (de) 2004-09-17
NZ337211A (en) 2000-12-22
US6747150B2 (en) 2004-06-08
ATE411324T1 (de) 2008-10-15
DK1627880T3 (da) 2008-12-08
LU91083I2 (fr) 2004-08-09
DE122004000025I2 (de) 2006-09-07
US8378099B2 (en) 2013-02-19
ES2199257T7 (es) 2010-03-31
US7531526B2 (en) 2009-05-12
CN1168633A (zh) 1997-12-24
US6617317B1 (en) 2003-09-09
CA2496538C (en) 2011-08-02
US6548668B2 (en) 2003-04-15
EP0788360A4 (de) 1998-05-06
NO2004004I1 (no) 2004-08-06
DK1312609T3 (da) 2006-05-15
NO971929D0 (no) 1997-04-25
US20060122390A1 (en) 2006-06-08
PT788360E (pt) 2003-10-31
NO2004004I2 (no) 2007-09-10
ATE241631T1 (de) 2003-06-15
IL137726A0 (en) 2001-10-31
FI20041415A (fi) 2004-11-03
US5780454A (en) 1998-07-14
US6066730A (en) 2000-05-23
MX9703063A (es) 1998-07-31
US20090247731A1 (en) 2009-10-01
DE69534727T2 (de) 2006-09-14
EP1312609A1 (de) 2003-05-21
FI971746A (fi) 1997-06-06

Similar Documents

Publication Publication Date Title
DE69535866D1 (de) Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
NO920767D0 (no) Pyranylcyanoguanidin-derivater
FI902710A0 (fi) Pyranylcyanoguanidinderivat.
HU905062D0 (en) Process for producing new 2-(rs)-substituted 2,3-dihydro-5-oxy-4,6,7-trimethyl-benzofurane compounds
ES2073495T3 (es) Benzotiazepinas.
HN1997000013A (es) Compuestos 1,4 dihidropiridina
PT916659E (pt) Processo para a producao de formilimidazolos
HN1997003676A (es) Derivados 6,5 heterobiciclicos sustituidos.
HN1997000104A (es) Derivados 6,6 heterociclicos sustituidos.
IT222268Z2 (it) Utensili per presse piegatrici.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition